CIK 0001689375
- Accelerated filer
- Smaller reporting company
- Emerging growth company
Entrada Therapeutics, Inc.
Sign in to watch- Ticker
- TRDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813983399
- Phone
- +1 857-305-1825
- Business address
- ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON, MA, 02210
- Former names
- CycloPorters, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $7,200,939
- in 8 filings
Net −$7,200,939. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 21 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-08-04 | KREHER NERISSA Chief Medical Officer | Option exercise 10b5-1 | +6,898 | $2.10 | $14K | 34,028 |
| 2023-08-04 | KREHER NERISSA Chief Medical Officer | Sale 10b5-1 | −6,898 | $14.14 | $98K | 27,130 |
| 2023-08-04 | KREHER NERISSA Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,898 | 88,012 | ||
| 2023-08-03 | KREHER NERISSA Chief Medical Officer | Option exercise 10b5-1 | +9,464 | $2.10 | $20K | 36,594 |
| 2023-08-03 | KREHER NERISSA Chief Medical Officer | Sale 10b5-1 | −9,464 | $14.74 | $140K | 27,130 |
| 2023-08-03 | KREHER NERISSA Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −9,464 | 94,910 | ||
| 2023-08-02 | KREHER NERISSA Chief Medical Officer | Option exercise 10b5-1 | +10,348 | $2.10 | $22K | 37,478 |
| 2023-08-02 | KREHER NERISSA Chief Medical Officer | Sale 10b5-1 | −9,280 | $15.09 | $140K | 28,198 |
| 2023-08-02 | KREHER NERISSA Chief Medical Officer | Sale 10b5-1 | −1,000 | $16.01 | $16K | 27,198 |
| 2023-08-02 | KREHER NERISSA Chief Medical Officer | Sale 10b5-1 | −68 | $16.82 | $1K | 27,130 |
| 2023-08-02 | KREHER NERISSA Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,348 | 104,374 | ||
| 2023-07-11 | WENTWORTH KORY JAMES Chief Financial Officer | Option exercise 10b5-1 | +3,884 | $2.10 | $8K | 40,631 |
| 2023-07-11 | WENTWORTH KORY JAMES Chief Financial Officer | Sale 10b5-1 | −3,884 | $18.00 | $70K | 36,747 |
| 2023-07-11 | WENTWORTH KORY JAMES Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,884 | 64,657 | ||
| 2023-07-11 | Dowden Nathan J Chief Operating Officer | Sale 10b5-1 | −3,897 | $18.05 | $70K | 35,376 |
| 2023-07-11 | Sethuraman Natarajan Chief Scientific Officer | Sale 10b5-1 | −14,852 | $18.04 | $268K | 153,447 |
| 2023-07-10 | WENTWORTH KORY JAMES Chief Financial Officer | Option exercise 10b5-1 | +6,116 | $2.10 | $13K | 42,863 |
| 2023-07-10 | WENTWORTH KORY JAMES Chief Financial Officer | Sale 10b5-1 | −6,116 | $17.98 | $110K | 36,747 |
| 2023-07-10 | WENTWORTH KORY JAMES Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,116 | 68,541 | ||
| 2023-07-10 | Dowden Nathan J Chief Operating Officer | Sale 10b5-1 | −3,200 | $18.00 | $58K | 39,273 |
Page 15 of 26 · 517 trades